Ipca Laboratories has announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported a standalone net profit of ₹387.29 crores, marking a substantial 27% increase compared to the same period last year. Consolidated net profit also saw a significant rise of 33% to ₹375.13 crores. Revenue from operations showed strong growth, with standalone revenue up 17% and consolidated revenue up 14%.
Ipca Laboratories Reports Strong Q2 FY27 Financials
Ipca Laboratories Limited has officially announced its unaudited financial results for the second quarter (Q2) and the first half (H1) of the financial year ending September 30, 2026. The company has demonstrated robust financial performance, with notable year-on-year growth across key metrics.
Standalone Performance Highlights
Q2 FY27
- Standalone Net Profit: The company reported a standalone net profit after tax of ₹387.29 crores for Q2 FY27, representing a significant increase of 27% compared to ₹304.74 crores in Q2 FY26.
- Revenue from Operations: Standalone revenue from operations grew by 17% to ₹2255.61 crores in Q2 FY27, up from ₹1930.32 crores in Q2 FY26.
- EBITDA Margin: Standalone EBITDA margin, before forex, other income, and exceptional items, stood at 26.61% for Q2 FY27, an improvement from 25.46% in Q2 FY26.
- Earnings Per Share (EPS): Basic and diluted EPS (after exceptional items) were ₹15.27, up 27% from ₹12.01 in the prior year period.
H1 FY27
- Standalone Net Profit: For the first half of FY27, standalone net profit after tax was ₹760.58 crores, a 34% increase from ₹566.78 crores in H1 FY26.
- Revenue from Operations: Standalone revenue from operations increased by 19% to ₹4374.85 crores in H1 FY27.
- EBITDA Margin: The standalone EBITDA margin was 26.45% for H1 FY27, compared to 24.68% in H1 FY26.
Consolidated Performance Highlights
Q2 FY27
- Consolidated Net Profit: Consolidated net profit after tax reached ₹375.13 crores, a 33% increase from ₹282.57 crores in Q2 FY26.
- Consolidated Net Total Income: Total consolidated income rose by 14% to ₹2934.97 crores in Q2 FY27.
- EBITDA Margin: Consolidated EBITDA margin stood at 22.97% for Q2 FY27, up from 21.68% in Q2 FY26.
H1 FY27
- Consolidated Net Profit: Consolidated net profit after tax for H1 FY27 was ₹777.02 crores, marking a significant 51% increase from ₹515.78 crores in H1 FY26.
- Consolidated Net Total Income: Total consolidated income grew by 17% to ₹5748.33 crores for H1 FY27.
Key Financials and Segment Performance
The company also provided a breakdown of its revenue, with Indian formulations income growing by 14% to ₹1157.20 crores in Q2 FY27 and exports income rising by 17% to ₹951.39 crores. The press release detailed performance for both standalone and consolidated entities across various product categories including Formulations and APIs. The Board of Directors approved these results, which were taken on record at their meeting held on November 5, 2026.
Source: BSE
